Sorrento Therapeutics Inc (SRNE)

[runcaly]

SCILEX HOLDING COMPANY, A SORRENTO COMPANY, AND VICKERS VANTAGE CORP. I ANNOUNCED TODAY THE FILING OF A REGISTRATION STATEMENT ON FORM S-4 WITH THE SECURITIES AND EXCHANGE COMMISSION RELATING TO THE PREVIOUSLY ANNOUNCED PROPOSED BUSINESS COMBINATION BETWEEN SCILEX AND VICKERS

PALO ALTO, Calif. and NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and Vickers Vantage Corp. I (Nasdaq: VCKA “Vickers”) today announced the filing of a Registration Statement on Form S-4 (the “Registration Statement”) by Vickers with the Securities and Exchange Commission (the "SEC") on May 13, 2022, relating to the previously announced proposed business combination between Scilex and Vickers (the "Business Combination").

The Registration Statement contains a preliminary proxy statement/prospectus in connection with the Business Combination. While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about Scilex and Vickers, as well as the proposed Business Combination.

About Scilex Holding Company